Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712265 | 0.94 | MAPT (0.33) | IDO1TDO2MAPTGAA | |
| SCHEMBL3384150 | 0.84 | MAPT (0.44) | IDO1TDO2MAPTGAA | |
| SCHEMBL8352236 | 0.79 | IDO1 (0.36) | IDO1TDO2MAPTGAA | |
| SCHEMBL8988199 | 0.79 | IDO1 (0.36) | IDO1TDO2 | |
| SCHEMBL13652549 | 0.75 | IDO1 (0.34) | IDO1TDO2GAA | |
| SCHEMBL26885063 | 0.75 | IDO1 (0.34) | IDO1TDO2 | |
| SCHEMBL22881094 | 0.73 | APLNR (0.33) | — | |
| SCHEMBL27115656 | 0.72 | IDO1 (0.32) | IDO1TDO2 | |
| SCHEMBL17194021 | 0.72 | IDO1 (0.32) | IDO1TDO2 | |
| SCHEMBL27115657 | 0.72 | IDO1 (0.32) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-8829196-B2 | TRPA1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829196-B2 | TRPA1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011043954-A1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043954-A1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-1914232-B1 | N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20080103178-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1914232-A1 | N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-7300947-B2 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20070015792-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | MSD K.K. (JP) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | IDO1 1451/4885TDO2 785/4885MAPT 1809/4885 |
| US-20070015792-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | OPRL1, OPRK1, GPR119 | IDO1 582/4885TDO2 1697/4885MAPT 768/4885 |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | IDO1 2715/4885TDO2 2988/4885MAPT 4131/4885 |
| US-20080103178-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | OPRL1, OPRK1, GPR119 | IDO1 582/4885TDO2 1697/4885MAPT 768/4885 |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | IDO1 1043/4885TDO2 1340/4885MAPT 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.